Price Movement and Market Context
On 24 Nov 2025, Shree Ganesh Biotech India’s stock price settled at Rs.0.64, representing its lowest level in the past year and an all-time low. This price is notably below its 52-week high of Rs.1.19, reflecting a substantial contraction in market value over the period. Despite the stock’s decline, the broader market has demonstrated positive momentum. The Sensex opened 88.12 points higher and was trading at 85,379.45, up 0.17% on the day, and remains within 0.49% of its 52-week high of 85,801.70. The index has also recorded a 2.6% gain over the last three weeks, supported by mega-cap stocks and bullish moving averages.
Shree Ganesh Biotech India’s share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward pressure on the stock relative to its recent trading history.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Financial Performance Overview
Over the last year, Shree Ganesh Biotech India’s stock has recorded a return of -37.50%, contrasting with the Sensex’s positive 7.90% performance during the same period. The company’s financial results for the nine months ended September 2025 reveal a contraction in net sales to Rs.5.16 crores, reflecting a decline of 44.64% compared to the previous period. Correspondingly, the net profit after tax (PAT) stood at a loss of Rs.0.61 crores, also showing a 44.64% reduction.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) remain negative, which adds to the cautious outlook on its financial health. The average EBIT to interest ratio is 0.91, indicating limited capacity to cover interest expenses from operating earnings. Additionally, the average return on equity (ROE) is 2.62%, signalling modest profitability relative to shareholders’ funds.
Liquidity and Operational Metrics
Shree Ganesh Biotech India’s debtor turnover ratio for the half year is recorded at 0.00 times, suggesting challenges in realising receivables efficiently. This metric points to potential cash flow constraints and may affect the company’s working capital management. The stock’s valuation appears elevated relative to its historical averages, contributing to perceptions of increased risk among market participants.
Shareholding Pattern and Market Position
The majority of Shree Ganesh Biotech India’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance trends amid evolving market conditions.
Considering Shree Ganesh Biotech India ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Comparison
While Shree Ganesh Biotech India’s stock has declined, the Pharmaceuticals & Biotechnology sector as a whole has experienced varied outcomes. The Sensex’s current bullish trend, supported by strong moving averages and mega-cap leadership, contrasts with the micro-cap’s performance. This divergence highlights the challenges faced by smaller companies in maintaining momentum amid broader market advances.
Summary of Key Concerns
The stock’s fall to Rs.0.64 reflects a combination of subdued sales, losses at the net profit level, and liquidity indicators that suggest operational strain. The negative EBITDA and limited interest coverage ratio further underscore financial pressures. These factors collectively contribute to the stock’s positioning below all major moving averages and its 52-week low status.
Market Outlook and Current Positioning
Despite the stock’s decline, the overall market environment remains positive, with the Sensex near its 52-week high and demonstrating resilience. Shree Ganesh Biotech India’s current valuation and financial metrics indicate a cautious stance among market participants, with the stock trading at levels that reflect the company’s recent performance and sector challenges.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
